finance
FDA Greenlights AstraZeneca & Daiichi's Lung Cancer Breakthrough: Enhertu Approval & Market Impact
The US Food and Drug Administration (FDA) has approved Enhertu (trastuzumab deruxtecan-nxki) from AstraZeneca and Daiichi Sankyo for a wider range of lung cancer patients. This expansion significantly broadens the drug's reach and offers new hope for those battling this aggressive disease. The appr